Rathi N. Pillai

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Scott Antonia, José A. López-Martín, Johanna C. Bendell et al. · The Lancet Oncology · 2016 · 1.3K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent

Alice O. Kamphorst, Andreas Wieland, Tahseen H. Nasti et al. · Science · 2017 · 1K citations · Full text

Life Sciences, Immunology, Oncology +16

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

Alice O. Kamphorst, Rathi N. Pillai, Shu Yang et al. · Proceedings of the National Academy of Sciences · 2017 · 881 citations · Full text

Life Sciences, Immunology, Oncology +17

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

Padmanee Sharma, Margaret K. Callahan, Petri Bono et al. · The Lancet Oncology · 2016 · 685 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

Badi El Osta, Madhusmita Behera, Sungjin Kim et al. · Journal of Thoracic Oncology · 2019 · 241 citations · Full text

Medicine, Molecular Genetics, Oncology +14